This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

STEGLATRO® (ertugliflozin) budget impact tool

  • The NHS spent £94.3 million on SGLT2i (sodium glucose co-transporters 2 inhibitors) in the 2018–2019 financial year1
  • STEGLATRO could reduce these costs by 20% as the acquisition cost is £93.73 per patient per year less than the other SGLT2s2

Discover how STEGLATRO could benefit your local healthcare economy

Start by selecting your CCG or local healthboard

Saving if all patients currently prescribed SGLT2is were prescribed STEGLATRO instead1

 

Start by selecting your CCG or local healthboard

Saving if all patients currently prescribed SGLT2is were prescribed STEGLATRO instead1

 

64.6% of type 2 diabetes mellitus (T2DM) may present without established cardiovascular disease (eCVD)3

Saving if all non-established CVD patients currently prescribed SGLT2is were prescribed STEGLATRO instead.1,3

 

Assumptions

  • Prices based on NHS list price
  • Annual savings per CCG calculated by applying the 20% difference in price of STEGLATRO versus the list price of the other SGLT2i therapy regimens over 12 months for all existing patients switched to STEGLATRO
  • Annual savings per CCG calculated by applying the 20% difference in price of STEGLATRO versus the list price of the other SGLT2i therapy regimens over 12 months for all existing without established CVD patients switched to STEGLATRO assuming 64.6% eligibility
  • This calculator assumes that all current SGLT2i patients are suitable for STEGLATRO. Please refer to the STEGLATRO Summary of Product Characteristics to ensure your patient is appropriate for STEGLATRO prior to prescribing4

About STEGLATRO?

 

Proven HbA1C reduction

STEGLATRO has proven efficacy in HbA1C reduction and has been extensively studied in a broad range of type 2 diabetes indications.4,5,6

 

Mono, dual and triple therapy

STEGLATRO has achieved a positive SMC assessment for mono, dual and triple therapy.7

 

Approved by NICE for T2DM

STEGLATRO has been approved by NICE as monotherapy or dual therapy (with metformin) for treating type 2 diabetes.8

 

Approved triple therapy regimen

STEGLATRO is the only SGLT2 inhibitor approved by NICE as triple therapy regimen with metformin and a dipeptidyl peptidase-4 (DPP-4) for treating type 2 diabetes.9

CCGs = Clinical Commissioning Groups; CVD = Cardiovascular Disease; SGLTs = Sodium Glucose Co-transporters; T2DM = Type 2 Diabetes Mellitus.

References

  1. Practice Level Prescribing Data, NHS Digital, https://digital.nhs.uk/data-and-information/publications/statistical/practice-level-prescribing-data, 18th December 2019. Contains information from NHS Digital, licenced under the current version of the Open Government Licence.
  2. NHS England & Wales Drug Tariff, January 2019. Accessed https://www.nhsbsa.nhs.uk/sites/default/files/2019-03/Drug%20 Tariff%20April%202019.pdf.
  3. Lautsch D, Wang T, Yang L, et al. Diabetes Ther. (2019). https://doi.org/10.1007/s13300-019-00698-9.
  4. Ertugliflozin Summary of Product Characteristics.
  5. Pratley RE, et al. (VERTIS FACTORIAL) randomized trial. Diabetes, Obesity and Metabolism. 2018 May;20(5):1111–20.
  6. Dagogo-Jack S, et al. (VERTIS SITA2) placebo‐controlled randomized study. Diabetes, Obesity and Metabolism. 2018 Mar;20(3):530–40.
  7. Scottish Medicine Consortium. https://www.scottishmedicines.org.uk/medicines-advice/ertugliflozin -steglatro-fullsubmission-smc2102/.
  8. NICE. Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes [TA 572]. 27 March 2019 https://www.nice.org.uk/guidance/ta572.
  9. NICE. Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583) https://www.nice.org.uk/search?q=TA583.

Supporting documentation

STEGLATRO® (ertugliflozin) 5 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

STEGLATRO® (ertugliflozin) 15 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

JANUVIA® (sitagliptin) 100 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

JANUVIA® (sitagliptin) 50 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

JANUVIA® (sitagliptin) 25 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-STE-00292 | Date of Preparation: January 2020